Published in J Infect Dis on August 01, 1982
Combination antifungal therapy. Antimicrob Agents Chemother (2004) 3.49
Compounds active against cell walls of medically important fungi. Clin Microbiol Rev (1993) 2.67
Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother (1991) 1.91
Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrob Agents Chemother (1989) 1.89
Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother (1993) 1.83
Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother (1995) 1.40
Nikkomycin Z supersensitivity of an echinocandin-resistant mutant of Saccharomyces cerevisiae. Antimicrob Agents Chemother (1995) 1.38
Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother (1992) 1.29
Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob Agents Chemother (1994) 1.23
Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus. Antimicrob Agents Chemother (1994) 1.09
Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Antimicrob Agents Chemother (1995) 1.07
Candida septic thrombosis of the great central veins associated with central catheters. Clinical features and management. Ann Surg (1985) 1.00
Multifactorial analysis of effects of interactions among antifungal and antineoplastic drugs on inhibition of Candida albicans growth. Antimicrob Agents Chemother (1989) 0.93
Medical management approach to infectious keratitis. Indian J Ophthalmol (2008) 0.93
Use of decimal assay for additivity to demonstrate synergy in pair combinations of econazole, nikkomycin Z, and ibuprofen against Candida albicans in vitro. Antimicrob Agents Chemother (1995) 0.92
In vitro interaction between amphotericin B and azoles in Candida albicans. Antimicrob Agents Chemother (1996) 0.89
Sensitivity of Candida albicans to amphotericin B administered as single or fractionated doses. Antimicrob Agents Chemother (1986) 0.87
Synergistic antifungal activity and reduced toxicity of liposomal amphotericin B combined with gramicidin S or NF. Antimicrob Agents Chemother (1987) 0.84
Novel synergism of two antifungal agents, copiamycin and imidazole. Antimicrob Agents Chemother (1983) 0.81
Effects of free and liposomal amphotericin B and gramicidin S alone and in combination on potassium leakage from human erythrocytes and Candida albicans. Antimicrob Agents Chemother (1989) 0.78
Interference with effects of amphotericin B on Candida albicans cells by 2-chloroethyl-1-nitrosoureas. Antimicrob Agents Chemother (1988) 0.75
Improved broad-host-range plasmids for DNA cloning in gram-negative bacteria. Gene (1988) 18.10
Variation in the susceptibility of strains of Staphylococcus aureus to oxacillin, cephalothin, and gentamicin. Antimicrob Agents Chemother (1976) 6.26
A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med (1979) 5.87
Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol (1986) 5.19
Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis (1992) 4.98
Classification of Histoplasma capsulatum isolates by restriction fragment polymorphisms. J Bacteriol (1986) 4.55
Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism). Proc Natl Acad Sci U S A (1972) 4.09
Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proc Soc Exp Biol Med (1971) 4.02
Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. N Engl J Med (1970) 3.74
Comparison of the in vitro activities of HR756 with cephalothin, cefoxitin, and cefamandole. Antimicrob Agents Chemother (1978) 3.29
Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother (1990) 3.26
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
Strategies in the treatment of systemic fungal infections. N Engl J Med (1980) 2.89
Evaluation of rooms with negative pressure ventilation used for respiratory isolation in seven midwestern hospitals. Infect Control Hosp Epidemiol (1993) 2.65
Antimicrobial misuse in patients with positive blood cultures. Am J Med (1989) 2.45
Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med (1988) 2.44
Antibiotic synergism against Listeria monocytogenes. Antimicrob Agents Chemother (1972) 2.36
Amphotericin B potentiation of rifampicin as an antifungal agent against the yeast phase of Histoplasma capsulatum. Science (1972) 2.31
New fluorescence assay for the quantitation of fungi. J Clin Microbiol (1989) 2.26
Potentiation of the antifungal effects of antibiotics by amphotericin B. Antimicrob Agents Chemother (1972) 2.24
Rapid radiometric method of testing susceptibility of mycobacteria and slow-growing fungi to antimicrobial agents. Antimicrob Agents Chemother (1974) 2.22
Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med (1987) 2.20
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17
Antifungal agents useful in therapy of systemic fungal infections. Annu Rev Pharmacol Toxicol (1983) 2.11
In vitro activity of HR 756, a new cephalosporin, against Neisseria gonorrhoeae. Antimicrob Agents Chemother (1979) 2.09
Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis (1986) 2.08
Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. 3. Osteomyelitis associated with vascular insufficiency. N Engl J Med (1970) 2.05
Typing of Histoplasma capsulatum by restriction fragment length polymorphisms in a nuclear gene. J Clin Microbiol (1992) 2.02
Interaction of plasma proteins and lipoproteins with amphotericin B. J Infect Dis (1984) 1.93
Use of mitochondrial and ribosomal DNA polymorphisms to classify clinical and soil isolates of Histoplasma capsulatum. Infect Immun (1989) 1.85
Comparison of the separation of Candida albicans chromosome-sized DNA by pulsed-field gel electrophoresis techniques. Nucleic Acids Res (1989) 1.79
Amphotericin B: delivery systems. Antimicrob Agents Chemother (1990) 1.78
Irreversible block of the mycelial-to-yeast phase transition of Histoplasma capsulatum. Science (1986) 1.78
Sensitive high-pressure liquid chromatographic assay for amphotericin B which incorporates an internal standard. Antimicrob Agents Chemother (1986) 1.77
Membrane lipid perturbation modifies the set point of the temperature of heat shock response in yeast. Proc Natl Acad Sci U S A (1996) 1.76
Isolation, characterization, and sequencing of Candida albicans repetitive element 2. Gene (1992) 1.73
Variable expression of a yeast-phase-specific gene in Histoplasma capsulatum strains differing in thermotolerance and virulence. Infect Immun (1989) 1.70
Classification of polyene antibiotics according to chemical structure and biological effects. Antimicrob Agents Chemother (1979) 1.69
Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem (2001) 1.69
Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis (1988) 1.68
Cell wall studies of Histoplasma capsulatum. Sabouraudia (1967) 1.68
Possible relationship of morphogenesis in pathogenic fungus, Histoplasma capsulatum, to heat shock response. Nature (1983) 1.67
Antifungal agents: recent developments. Annu Rev Microbiol (1977) 1.66
Correlation between pathogenicity and temperature sensitivity in different strains of Histoplasma capsulatum. J Clin Invest (1986) 1.65
Listeriosis in humans: an evaluation. J Infect Dis (1971) 1.63
Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B. Antimicrob Agents Chemother (1985) 1.62
Amphotericin B. Old drug, new therapy.?2110. JAMA (1975) 1.61
Temperature-sensitive variants of Histoplasma capsulatum isolated from patients with acquired immunodeficiency syndrome. J Infect Dis (1990) 1.60
Characterization of the binding of amphotericin B to Saccharomyces cerevisiae and relationship to the antifungal effects. Antimicrob Agents Chemother (1974) 1.60
Antimicrobial susceptibility testing of six clinical isolates of Aspergillus. Antimicrob Agents Chemother (1976) 1.59
Cutaneous mycobacteriosis: analysis of 34 cases with a new classification of the disease. Medicine (Baltimore) (1981) 1.57
Histoplasmosis. An illustrative case with unusual vaginal and joint involvement. Arch Dermatol (1969) 1.55
Synergistic effect of amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea against a transplantable AKR leukemia. Cancer Res (1974) 1.52
Establishment of medaka (Oryzias latipes) transgenic lines with the expression of green fluorescent protein fluorescence exclusively in germ cells: a useful model to monitor germ cells in a live vertebrate. Proc Natl Acad Sci U S A (2001) 1.48
RNA metabolism during morphogenesis in Histoplasma capsulatum. J Gen Microbiol (1974) 1.45
Regulation of dimorphism in the pathogenic fungus Histoplasma capsulatum. Nature (1977) 1.44
Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res (2000) 1.43
A new therapeutic approach to Candida infections. A preliminary report. Arch Intern Med (1972) 1.42
Modulation of the macrophage oxidative burst by Histoplasma capsulatum. J Immunol (1987) 1.42
Dimorphism in Histoplasma capsulatum: a model for the study of cell differentiation in pathogenic fungi. Microbiol Rev (1989) 1.41
Role of cysteine in regulating morphogenesis and mitochondrial activity in the dimorphic fungus Histoplasma capsulatum. Proc Natl Acad Sci U S A (1981) 1.38
Activity of amphotericin B, 5-fluorocytosine, and rifampin against six clinical isolates of Aspergillus. Antimicrob Agents Chemother (1976) 1.36
Contamination of flexible fiberoptic bronchoscopes with Mycobacterium chelonae linked to an automated bronchoscope disinfection machine. Am Rev Respir Dis (1992) 1.33
Comparison of the in vitro and in vivo activity of the bis-triazole derivative UK 49,858 with that of amphotericin B against Histoplasma capsulatum. Antimicrob Agents Chemother (1986) 1.33
Therapy of murine aspergillosis with amphotericin B in combination with rifampin of 5-fluorocytosine. Antimicrob Agents Chemother (1977) 1.32